EXEL Exelixis Inc.

17.67
+1.15  (+7%)
Previous Close 16.52
Open 16.99
Price To Book 3.2
Market Cap 5,396,298,551
Shares 305,393,240
Volume 6,164,627
Short Ratio
Av. Daily Volume 3,740,472
Stock charts supplied by TradingView

NewsSee all news

  1. ALEXANDRIA REAL ESTATE EQUITIES, INC. (FormDEF 14A)

  2. Exelixis Announces Partner Takeda Receives Approval in Japan for CABOMETYX® (cabozantinib) Tablets for the Treatment of Curatively Unresectable or Metastatic Renal Cell Carcinoma

    Exelixis, Inc. (NASDAQ:EXEL) today announced that Takeda Pharmaceutical Company Limited (Takeda), its partner responsible for the clinical development and commercialization of CABOMETYX® (cabozantinib) in Japan,

  3. Exelixis Announces George A. Scangos, Ph.D. to Retire From Its Board of Directors

    Exelixis, Inc. (NASDAQ:EXEL) today announced that George A. Scangos, Ph.D. has notified the company of his decision to retire from the Exelixis Board of Directors. Dr. Scangos will not stand for re-election to the Board

  4. Exelixis Announces Webcasts of Investor Conference Presentations in March

    - Presentations to be webcast on www.exelixis.com - Exelixis, Inc. (NASDAQ:EXEL) today announced that members of Exelixis' management team will provide a corporate overview at the following investor conferences in

  5. Exelixis Announces First 100 Patients Enrolled in Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Relapsed Radioiodine-Refractory Differentiated Thyroid Cancer

    – Analysis for the co-primary endpoint of objective response rate and an interim analysis of progression-free survival expected in the second half of 2020 – Exelixis, Inc. (NASDAQ:EXEL) today announced enrollment of

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data did not meet primary endpoint - June 20, 2019.
IMspire170 - cobimetinib and atezolizumab
First-line BRAF wild-type metastatic or unresectable locally advanced melanoma
Phase 3 data released May 10, 2018. Primary endpoint not met.
IMblaze370 - cobimetinib and atezolizumab
Third-line advanced or metastatic colorectal cancer
Phase 2 ongoing.
CABOMETYX (cabozantinib)
Recurrent endometrial cancer
Phase 3 data due 1H 2020.
CABOMETYX (cabozantinib) with Opdivo and Yervoy - CheckMate 9ER
First-line renal cell carcinoma
Approved November 29, 2012.
Cabozantinib
Medullary thyroid cancer
Phase 3 trial met primary endpoint - September 24, 2017. Japanese regulatory filing due 1Q 2018.
Esaxerenone (CS-3150)
Essential hypertension
Late breaker at ESMO September 10, 2017 showed PFS 8.6 months versus 5.3 months for sunitinib. HR 0.48. PDUFA date under priority review for sNDA February 15, 2018. Approval announced December 19, 2017.
Cabozantinib - CABOSUN
First-Line RCC - cancer
FDA Approval announced January 14, 2019.
Cabozantinib (CELESTIAL)
Advanced hepatocellular cancer (HCC)
Approved April 25 2016.
CABOMETYX (cabozantinib)
Metastatic renal cell cancer (RCC)
Approved November 10, 2015.
Vemurafenib
BRAF V600 Mutation-Positive Advanced Melanoma - Cancer
Phase 3 COMET-2 trial did not meet endpoint December 1 2014
Cabozantinib
Cancer - Castration-Resistant Prostate Cancer
Phase 3 interim analysis due 2H 2020.
Cabozantinib - COSMIC-311
Thyroid Carcinoma
Phase 3 trial met primary endpoint - December 13, 2019.`
IMspire150 - cobimetinib, atezolizumab and vemurafenib - TRILOGY
BRAF V600 mutation-positive metastatic or unresectable locally advanced melanoma
Phase 1b data at ASCO GU noted ORR 32%.
Cabozantinib + atezolizumab (TECENTRIQ) COSMIC-021
Solid tumors
Phase 3 PFS and interim OS analysis due 2H 2020.
CABOMETYX (cabozantinib) + atezolizumab (TECENTRIQ) - (COSMIC-312)
Hepatocellular Carcinoma
Phase 1 trial initiation announced February 12, 2019.
XL092
Solid tumors
Phase 3 data due 2022.
Cabozantinib and Nivolumab and Ipilimumab (COSMIC-313)
Renal Cell Carcinoma
Phase 4 PFS data due 2020.
Cabozantinib
Medullary Thyroid Cancer
Phase 1b ORR 19% (cabozantinib and nivolumab) /29% (cabozantinib, nivolumab and ipilimumab) - January 24, 2020.
Cabozantinib /nivolumab and ipilimumab (CM-040)
Hepatocellular cancer

Latest News

  1. ALEXANDRIA REAL ESTATE EQUITIES, INC. (FormDEF 14A)

  2. Exelixis Announces Partner Takeda Receives Approval in Japan for CABOMETYX® (cabozantinib) Tablets for the Treatment of Curatively Unresectable or Metastatic Renal Cell Carcinoma

    Exelixis, Inc. (NASDAQ:EXEL) today announced that Takeda Pharmaceutical Company Limited (Takeda), its partner responsible for the clinical development and commercialization of CABOMETYX® (cabozantinib) in Japan,

  3. Exelixis Announces George A. Scangos, Ph.D. to Retire From Its Board of Directors

    Exelixis, Inc. (NASDAQ:EXEL) today announced that George A. Scangos, Ph.D. has notified the company of his decision to retire from the Exelixis Board of Directors. Dr. Scangos will not stand for re-election to the Board

  4. Exelixis Announces Webcasts of Investor Conference Presentations in March

    - Presentations to be webcast on www.exelixis.com - Exelixis, Inc. (NASDAQ:EXEL) today announced that members of Exelixis' management team will provide a corporate overview at the following investor conferences in

  5. Exelixis Announces First 100 Patients Enrolled in Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Relapsed Radioiodine-Refractory Differentiated Thyroid Cancer

    – Analysis for the co-primary endpoint of objective response rate and an interim analysis of progression-free survival expected in the second half of 2020 – Exelixis, Inc. (NASDAQ:EXEL) today announced enrollment of

  6. Exelixis Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

    - Total Revenue of $240.3 Million for the Fourth Quarter of 2019, $967.8 Million for the Full Year 2019 - - GAAP Diluted EPS of $0.22 for the Fourth Quarter of 2019, $1.02 for the Full Year 2019 - - Non-GAAP Diluted

  7. Exelixis to Release Fourth Quarter and Full Year 2019 Financial Results on Tuesday, February 25, 2020

    –Conference Call and Webcast to Follow at 5:00 p.m. EST / 2:00 p.m. PST– Exelixis, Inc. (NASDAQ:EXEL) announced today that its fourth quarter and full year 2019 financial results will be released on Tuesday, February

  8. Exelixis Announces Encouraging Results for Cabozantinib in Combination With Atezolizumab in Metastatic Castration-Resistant Prostate Cancer

    Data from the COSMIC-021 trial will be presented on Thursday, February 13, 2020 at the American Society of Clinical Oncology's Genitourinary Cancers Symposium Exelixis, Inc. (NASDAQ:EXEL) today announced encouraging

  9. Exelixis Announces Webcasts of Investor Conference Presentations in February

    Presentations to be webcast on www.exelixis.com Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will be presenting at the following

  10. Exelixis Announces Partner Takeda Files New Drug Application in Japan for CABOMETYX® (cabozantinib) for Advanced Hepatocellular Carcinoma

    – Submission based on two clinical trials in patients with advanced hepatocellular carcinoma who had received prior systemic therapy – Exelixis, Inc. (NASDAQ:EXEL) today announced that Takeda Pharmaceutical Company

  11. Exelixis Announces Results for Combination of Cabozantinib and Nivolumab With or Without Ipilimumab in Advanced Hepatocellular Carcinoma

    – Data from the CheckMate 040 trial presented at the 2020 American Society of Clinical Oncology's Gastrointestinal Cancers Symposium – Exelixis, Inc. (NASDAQ:EXEL) today announced phase 1/2 clinical trial results from

  12. Exelixis Outlines Key Priorities and Anticipated Milestones for 2020-21, Announces Preliminary Fourth Quarter and Full Year 2019 Financial Results, and Provides 2020 Financial Guidance

    – Company announces anticipated timelines for data readouts from six cabozantinib potentially label-enabling clinical studies and up to three new potential IND candidates – – Presentation and webcast at 2020 J.P.

  13. Exelixis to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 14, 2020

    — Presentation to be webcast on www.exelixis.com — Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will provide a corporate overview

  14. Exelixis Further Expands Prostate Cancer Cohort in Phase 1b COSMIC-021 Trial of Cabozantinib in Combination with Atezolizumab in Patients with Advanced Solid Tumors

    – Based on continued encouraging efficacy and safety data, metastatic castration-resistant prostate cancer cohort further expanded to 130 patients – – Initial data to be presented on

  15. Exelixis Enters into a Clinical Collaboration for Three Phase 3 Combination Trials for Patients with Advanced Solid Tumors

    – New pivotal trials will evaluate the combination of cabozantinib and atezolizumab in patients with advanced non-small cell lung cancer, castration-resistant prostate cancer and renal cell carcinoma – – Collaboration

  16. Exelixis Announces Positive Results From IMspire150, the Phase 3 Trial of Atezolizumab Plus Cotellic and Vemurafenib in People With Previously Untreated BRAF V600 Mutation-Positive Advanced Melanoma

    Exelixis, Inc. (NASDAQ:EXEL) today announced positive results from IMspire150, the phase 3 trial of atezolizumab (TECENTRIQ®), cobimetinib (COTELLIC®) and vemurafenib (ZELBORAF®) in people with previously untreated BRAF

  17. Exelixis Announces Webcasts of Investor Conference Presentations in December

    – Presentations to be webcast on www.exelixis.com – Exelixis, Inc. (NASDAQ:EXEL) today announced that members of Exelixis' management team will provide an overview of the company at the following investor conferences

  18. Exelixis to Present at the Stifel 2019 Healthcare Conference on November 19, 2019

    – Presentation to be webcast on www.exelixis.com – Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will provide a corporate overview

  19. Exelixis' Partner Ipsen Announces Health Canada's Approval of CABOMETYX® (cabozantinib) Tablets for the Treatment of Patients With Previously Treated Advanced Hepatocellular Carcinoma

    – Approval based on statistically significant and clinically meaningful overall survival benefit demonstrated in the CELESTIAL phase 3 pivotal trial – Exelixis, Inc. (NASDAQ:EXEL) today announced that its partner Ipsen

  20. Exelixis' Collaborator Daiichi Sankyo Announces Positive Results From Phase 3 Pivotal Trial of Esaxerenone in Patients With Diabetic Nephropathy

    -- Results being presented today in a late-breaking presentation (abstract TH-PO1201) at Kidney Week 2019, the annual meeting of the American Society of Nephrology in Washington, D.C. Exelixis, Inc. (NASDAQ:EXEL)

  21. Invenra Announces Expansion of Collaboration with Exelixis

    Invenra Inc. announced that it has expanded its collaboration with Exelixis, Inc. (NASDAQ:EXEL). Exelixis and Invenra had entered into a collaboration on May 2nd, 2018 to discover and develop multispecific antibodies

  22. Exelixis Announces Third Quarter 2019 Financial Results and Provides Corporate Update

    - Total Revenue of $271.7 Million, Cabozantinib Franchise Revenue of $191.8 Million - - GAAP Diluted EPS of $0.31, Non-GAAP Diluted EPS of $0.34 - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis,

  23. Exelixis to Present at the 2019 Cantor Global Healthcare Conference on October 2, 2019

    – Presentation to be webcast on www.exelixis.com – Exelixis, Inc. (NASDAQ:EXEL) today announced that members of Exelixis management will provide a corporate overview at the 2019 Cantor Global Healthcare Conference,

  24. Exelixis to Present at the Morgan Stanley 17th Annual Global Healthcare Conference on September 10, 2019

    – Presentation to be webcast on www.exelixis.com – Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will provide a corporate overview